致力於納米轉化醫學研究，主要研究方向：

1、核酸藥物（疫苗）開發及其納米靶向遞送係統研究；

2、生物材料合成及其微納結構調控幹細胞命運器官再造。

1.國家重點研發計劃課題，誘導周圍神經和血管原位再生的組織微環境適配導管支架研究，782萬元，2019-2023，負責人

2.國家科技重大專項，抗骨關節炎siRNA候選藥物臨床前研究，303.12萬元，2018-2020，子任務負責人

3.廣東省科技計劃項目，多功能聚羥基脂肪酸酯（PHAs）在siRNA藥物傳遞係統的研究，50萬元，2020-2021，負責人

4.廣州開發區國際科技合作項目，靶向腫瘤的小幹擾核酸藥物傳遞係統研究開發，200萬元，2019-2020，子任務負責人

5.廣州市對外科技合作專題，合理的設計和開發信使核糖核酸（mRNA）納米轉染試劑, 100萬元，2016-2018，負責人

1、2017年：“珠江人才計劃”高層次人才；

2、2013年：中國自費優秀留學生國家級獎項。

在高水平雜誌發表50餘篇論文，累計影響因子380，10篇書章節，主編撰寫英文論著一部，申請/授權國內和國際專利共8項。

發表論文（(^#Join first co-author）

1.Wu LP, Ficker M, Christensen JB, Simberg，D Trohopoulos PN, Moghimi SM*.(2021).Dendrimer end-terminal motif-dependent evasion of human complement and complement activation through IgM hitchhiking.Nature Communications, 12, 4858.

2.Deng W, Zhang Y, Wang W, Song A, Mukama O, Huang J, Han X, Deng S, Lin Z, Habimana JD, Huang R, Peng K, Ni B, Zhang S, Yan X, Li J,Wu LP*, Li Z*.(2021) Hair follicle-derived mesenchymal stem cells decrease alopecia areata mouse hair loss and reduce inflammation around the hair follicle.Stem Cell Research & Therapy,12, 548

3.Pannuzzo M^#, Esposito S^#,Wu LP^#, Key J, Aryal S, Celia C, Marzio LD, Moghimi SM*, Decuzzi P*.(2020)Overcoming nanoparticle-mediated complement activation by surface PEG-pairing.Nano letters, 20: 4312-4321.

4.Wu LP*, Ahmadvand D, Su JA, Hall A, Tan XL, Farhangrazi AZ, Moghimi SM*.(2019).Crossing the blood-brain-barrier with nanoligand drug carriers self-assembled from a phage display peptide.Nature Communications, 10, 4635.

5.Wu LP*, Wang DY, Li ZB. (2020). Grand challenges in nanomedicine.Materials Science and Engineering C, 106, 110302.

6.Xu Z, Wang D, Cheng Y, Yang M,Wu LP*. (2018). Polyester based nanovehicles for siRNA delivery. Materials Science and Engineering C, 92, 1006–1015.

7.Wu LP, Ficker M, Mejls？e SL, Hall A, Paolucci V, Christensen JB, Trohopoulos PN, Moghimi SM*. (2017). Poly-(amidoamine) dendrimers with a precisely core positioned sulforhodamine B molecule for comparative biological tracing and profiling.Journal of Controlled Release, 246, 88-97.

8.Wang D,Wu LP*. (2017). Nanomaterials for delivery of nucleic acid to the central nervous system (CNS).Materials Science and Engineering: C, 70, 1039–1046.

9.Wu LP, Uldahl KB, Chen FF, Benasutti H, Logvinski D, Vu V,. Banda NK, Peng X, Simberg D, Moghimi SM*. (2017) .Interaction of extremophilic archaeal viruses with human and mouse complement system and viral biodistribution in mice.Molecular Immunology, 90:273-279.

10.Wu LP*, Moghimi SM. (2016) A nanoengineered peptidic delivery system with specificity for human brain capillary endothelial cells.Nanomedicine: NBM, 12(2), 474-475.

11.Han J^#,Wu LP^#, Hou J, Zhao D, Xiang H*. (2015). Biosynthesis, Characterization and Hemostasis Potential of Tailor-Made Poly (3-hydroxybutyrate-co-3-hydroxyvalerate) Produced by Haloferax mediterranei.Biomacromolecules，16 (2), 578–588

12.Wu LP, Ficker M, Christensen JB, Trohopoulos PN, Moghimi SM*. (2015). Dendrimers in Medicine: Therapeutic Concepts and Pharmaceutical Challenges.Bioconjugate chemistry，26(7), 1198-1211.

13.Wu LP, Wang DY, Parhamifar L, Hall A, Chen G-Q, Moghimi, SM*. (2014). Poly (3-hydroxybutyrate-co-R-3-hydroxyhexanoate) Nanoparticles with Polyethylenimine Coat as Simple, Safe, and Versatile Vehicles for Cell Targeting: Population Characteristics, Cell Uptake, and Intracellular Trafficking.Advanced healthcare materials, 3(6), 817-824.

14.Wu LP^#, You ML^#, Wang DY, Peng GF, Wang ZH, CHEN G-Q*. (2013). Fabrication of Carbon Nanotubes (CNTs)/ Poly(3-hydroxyburyrate-co-3-hydroxyhexanoate) (PHBHHx) Nanocomposite Films for Human Mesenchymal Stem Cells (hMSCs) Differentiation.Polymer Chemistry,4, 4490-4498.

15.Wu LP^#, Tripathi L^#, Chen JC, Chen G-Q*. (2012).Synthesis of diblock copolymer poly-3-hydroxybutyrate-block-poly-3-hydroxy -hexanoate [PHB-b-PHHx] by a beta-oxidation weakened Pseudomonas putida KT2442.Microbial Cell Factories, 11:44.

16.Wu LP, Wang XJ, Cheng ST, Xu KT*.(2010). Synthesis, characterizations and biocompatibility of novel biodegradable star block copolymers based on poly[(R)-3-hydroxybutyrate] and poly(ε-caprolactone).Acta Biomaterialia,6, 1079-1089.

17.Wu LP, Cheng ST, Li ZB, Chen G-Q*, Xu KT*. (2008). Synthesis, characterization and biocompatibility of novel biodegradable poly[((R)-3-hydroxybutyrate)-block-(D,L-lactide)- block-(ε-caprolactone)] triblock copolymers.Polymer International, 57, 939-949.

18.Kim HS, Chen JY,Wu LP, Wu JH, Xiang H*, Leong KW, Han J*. (2020)Prevention of excessive scar formation using nanofibrous meshes made of biodegradable elastomer poly(3-hydroxybutyrate- co-3-hydroxyvalerate).Journal of Tissue Engineering,11, 1–12.

19.Xu Z, Wang D, Cheng Y, Yang M, 2.Wu LP*. (2018). Polyester based nanovehicles for siRNA delivery.Materials Science and Engineering C, 92, 1006–1015.

20.Hall A , Maynard S,Wu LP, Merchut-Maya JM, Strauss R, Moghimi SM, Bartek J. (2019) Perturbation of mitochondrial bioenergetics by polycations counteracts resistance to BRAFE600 inhibition in melanoma cells.Journal of Controlled Release, 309, 158–172.

21.Xue Q, Liu X, Lao YH,Wu LP, Wang D, Zuo Z, Chen J, Hou J, Bei Y, Wu X, Leong KW, Xiang H, Han J*. (2018). Anti-infective biomaterials with surface-decorated tachyplesin I.Biomaterials, 178, 351-362.

22.Chen C^#, Wang G^#, Griffin J, Brenneman B, Banda N, Holers V, Backos D,Wu LP, Moghimi SM, Simberg D*. (2017). Complement proteins bind to nanoparticle protein corona and undergo dynamic exchangein vivo.Nature Nanotechnology, 12(4), 387-393.

23.Wang D,Wu LP*. (2017). Nanomaterials for delivery of nucleic acid to the central nervous system (CNS).Materials Science and Engineering: C, 70, 1039–1046.

24.Uldahl KB^#,Wu LP^#, Hall A, Papathanasiou P, Peng X*, Moghimi SM*. (2017). Recognition of extremophilic archaeal viruses by eukaryotic cells: a promising nanoplatform from the third domain of life.Scientific Reports, 6, 37966.

25.Han J*,Wu LP, Liu XB, Hou J, Zhao LL, Chen JY, Zhao DH, Xiang H*. (2017) Biodegradation and biocompatibility of haloarchaea-produced poly(3-hydroxybutyrate-co-3-hydroxyvalerate) copolymers.Biomaterials, 139 172-186.

26.Ordó？ez-Gutiérrez L, Posado-Fernández A, Ahmadvand D, Lettiero B,Wu LP, Antón, M, Floresc O, Moghimi SM*, Wandosell F*. (2017). ImmunoPEGliposome-mediated reduction of blood and brain amyloid levels in a mouse model of Alzheimer's disease is restricted to aged animals.Biomaterials, 112, 141-152.

27.Azmi ID, Wibroe PP,Wu LP, Kazem AI, Amenitsch H, Moghimi S. M*, Yaghmur, A*. (2016). A structurally diverse library of safe-by-design citrem-phospholipid lamellar and non-lamellar liquid crystalline nano-assemblies.Journal of Controlled Release, 239, 1-9.

28.Inturi S, Wang G, Chen F, Banda NK, Holers VM,Wu LP, Moghimi SM, Simberg D*. (2015). Modulatory Role of Surface Coating of Superparamagnetic Iron Oxide Nanoworms in Complement Opsonization and Leukocyte Uptake.ACS nano, 9(11), 10758-10768.

29.Hall A,Wu LP, Parhamifar L, Moghimi SM*. (2015). Differential modulation of cellular bioenergetics by poly (L-lysine) s of different molecular weights.Biomacromolecules, 16(7), 2119-2126.

30.Meng DC, Wang Y,Wu LP, Shen R, Chen JC, Wu Q, Chen G-Q*. (2015). Production of poly (3-hydroxypropionate) and poly (3-hydroxybutyrate-co-3-hydroxypropionate) from glucose by engineering Escherichia coli.Metabolic engineering, 29, 189-195.

31.Tripathia L,Wu LP, Meng DC, Chen JC, WU Q, Chen G-Q*. (2013). Pseudomonas putida KT2442 as a platform for the biosynthesis of polyhydroxyalkanoates with adjustable monomer contents and compositions.Bioresource Technology,142, 225-231.

32.Tripathia L,Wu LP, Meng DC, Chen JC, Chen G-Q*. (2013). Biosynthesis and characterization of block copolymer of P(3-Hydroxypropionate)-block-P(4-Hydroxybutyrate) from recombinant escherichia coli.Biomacromolecules, 14, 862–870.

發明專利

1.一種核酸遞送係統及其製備方法和應用。專利號：2021105723647。

2.一種抗疲勞雙親性有機水凝膠及其製備方法和應用。專利號：2021105738657。

3.一種多孔聚羥基脂肪酸酯聚合物微球的微流控製備方法及製備得到的多孔聚合物微球及應用。專利號：2021105727347。

4.一種抑製sFRP1基因表達的siRNA及其應用。專利號：201811607298.7。

5.Peptidic nanodelivery composition targeting two receptors. PCT：PCT/EP2014/067651.

6.Nano-systems for therapy and/or diagnosis and/or therapy monitoring and/or theranostics of disease. PCT：PCT/EP2017/060579.